How we evaluate might be the easiest question to answer

August 7, 2019 Latest News Comment

This is a preview of subscriber content

Subscribe now to continue reading.

If we start with the objective of providing equitable access to these therapies, how they are evaluated is only one question. In fact, in the emerging era of personalised medicine, it may be the easiest question to answer. …

Subscribe now to continue reading.

Latest Video

An exceptional outcome that must not become an exception
October 18, 2025 - Latest News
BMS says September outcome could set a new policy benchmark for access
October 18, 2025 - Latest News
Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access
October 18, 2025 - Latest News
Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer
October 18, 2025 - Latest News
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 - Latest News

How we evaluate might be the easiest question to answer

This is a preview of subscriber content

Latest Video

Most Read

An exceptional outcome that must not become an exception

BMS says September outcome could set a new policy benchmark for access

Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access

Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer

New combination therapy sets landmark survival benchmark in bladder cancer treatment

New Stories

Vaccine confidence slips as Australians grow more concerned about access to healthcare

NZ's Pharmac proposes new rules to manage 'Options for Investment' list

Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies

Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum

Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome

Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion

Algorae partners with Cadila Pharmaceuticals to launch therapies in Australia and New Zealand

Sign In

How we evaluate might be the easiest question to answer

This is a preview of subscriber content

Latest Video

Most Read

An exceptional outcome that must not become an exception

BMS says September outcome could set a new policy benchmark for access

Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access

Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer

New combination therapy sets landmark survival benchmark in bladder cancer treatment

Follow Us

New Stories

Vaccine confidence slips as Australians grow more concerned about access to healthcare

NZ's Pharmac proposes new rules to manage 'Options for Investment' list

Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies

Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum

Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome

Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion

Algorae partners with Cadila Pharmaceuticals to launch therapies in Australia and New Zealand